Home » Osteologix to File for EU Marketing Authorization for Osteoporosis Drug
Osteologix to File for EU Marketing Authorization for Osteoporosis Drug
Osteologix Inc. announced Wednesday that the company anticipates that it will be prepared to file a marketing application in 2011 in the European Union
for its proprietary second-generation strontium therapy, NB S101 (strontium malonate).
RTTNews
RTTNews
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May